Study Using CP-461 to Treat Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00036075
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to investigate whether an investigational drug, CP-461, is safe and effective for the treatment of patients with prostate cancer and who have measurable disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Columbia Presbyterian Medical Center
🇺🇸New York, New York, United States
University of Washington
🇺🇸Seattle, Washington, United States
Columbia Presbyterian Medical Center🇺🇸New York, New York, United States